The cGAS-STING pathway as a novel therapeutic strategy for pancreatic diseases

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Cytokine Pub Date : 2024-11-10 DOI:10.1016/j.cyto.2024.156801

Zhengda Pei , Mengxiang Tian

{"title":"The cGAS-STING pathway as a novel therapeutic strategy for pancreatic diseases","authors":"Zhengda Pei , Mengxiang Tian","doi":"10.1016/j.cyto.2024.156801","DOIUrl":null,"url":null,"abstract":"<div><div>The Cyclic GMP-AMP synthase (cGAS)-Stimulator of interferon genes <span><span>[1]</span></span> signaling pathway has emerged as a pivotal immune response mechanism, activating immune defenses upon detection of both exogenous and endogenous DNA within cells. Its activation is intricately linked to various diseases and inflammatory processes, spanning autoimmune disorders, infectious ailments, and malignancies. Among pancreatic diseases, encompassing acute pancreatitis, chronic pancreatitis, and pancreatic cancer, current clinical treatment efficacy remains suboptimal. Here, we elucidate the molecular intricacies of the cGAS-STING signaling pathway and delineate its therapeutic potential in acute pancreatitis, chronic pancreatitis, and pancreatic cancer. Additionally, we offer an overview of recent advancements in STING agonists and antagonists, assessing their therapeutic potential in pancreatic-related disorders. In summary, by exploring the multifaceted roles of the cGAS-STING signaling pathway and its implications in pancreatic diseases, we aim to shed light on potential avenues for therapeutic intervention and management in these challenging clinical contexts.</div></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"184 ","pages":"Article 156801"},"PeriodicalIF":3.7000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624003053","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Cyclic GMP-AMP synthase (cGAS)-Stimulator of interferon genes [1] signaling pathway has emerged as a pivotal immune response mechanism, activating immune defenses upon detection of both exogenous and endogenous DNA within cells. Its activation is intricately linked to various diseases and inflammatory processes, spanning autoimmune disorders, infectious ailments, and malignancies. Among pancreatic diseases, encompassing acute pancreatitis, chronic pancreatitis, and pancreatic cancer, current clinical treatment efficacy remains suboptimal. Here, we elucidate the molecular intricacies of the cGAS-STING signaling pathway and delineate its therapeutic potential in acute pancreatitis, chronic pancreatitis, and pancreatic cancer. Additionally, we offer an overview of recent advancements in STING agonists and antagonists, assessing their therapeutic potential in pancreatic-related disorders. In summary, by exploring the multifaceted roles of the cGAS-STING signaling pathway and its implications in pancreatic diseases, we aim to shed light on potential avenues for therapeutic intervention and management in these challenging clinical contexts.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

将 cGAS-STING 通路作为胰腺疾病的新型治疗策略。

环状 GMP-AMP 合成酶（cGAS）-干扰素基因刺激器[1]信号通路已成为一种关键的免疫反应机制，在检测到细胞内的外源性和内源性 DNA 时激活免疫防御机制。它的激活与各种疾病和炎症过程密切相关，包括自身免疫性疾病、传染性疾病和恶性肿瘤。在包括急性胰腺炎、慢性胰腺炎和胰腺癌在内的胰腺疾病中，目前的临床治疗效果仍不理想。在此，我们阐明了 cGAS-STING 信号通路的分子复杂性，并描述了其在急性胰腺炎、慢性胰腺炎和胰腺癌中的治疗潜力。此外，我们还概述了 STING 激动剂和拮抗剂的最新进展，评估了它们在胰腺相关疾病中的治疗潜力。总之，通过探索 cGAS-STING 信号通路的多方面作用及其在胰腺疾病中的影响，我们旨在阐明在这些具有挑战性的临床环境中进行治疗干预和管理的潜在途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.